.jpg)
Pfizer is set to acquire Seagen for $43 billion and create a new oncology division
13 Dec 2023
In a significant move, Pfizer has announced its anticipation of concluding the $43 billion deal to acquire cancer drug maker Seagen by 16 December 2023.
Moderna sues Pfizer-BioNtech for patent violation
02 Sep 2022
According to Moderna, Pfizer-BioNTech copied mRNA technology that Moderna had patented between 2010 and 2016, well before Covid-19 emerged in 2019
Pfizer eyes a market gatecrash as India’s Covid tally mounts
04 May 2021
US pharma giant Pfizer is trying to convince Indian authorities that there is no need for regulatory scrutiny for its corona virus vaccine that added $3.5 billion to its revenue in the first three months of this year, since it is approved by regulatory authorities in the US, Britain, Japan and the WHO, all of which India endorses
Pfizer to acquire cancer drug maker Array Biopharma for $10.6 bn
18 Jun 2019
Array’s Braftovi and Mektovi, launched last July for the deadliest form of skin cancer at a price of $22,000 per month, had sales of around $72 million over their first nine months, besides revenue from royalty and licensing deals
Stay ahead with Informachine News Trackers! Follow your selected sources, track business news with relevant keywords, and organize seamlessly using labels and bookmarks.
Get the business updates you need, fast, focused, and tailored just for you. Save time, stay informed, and never miss a beat!
Latest articles on Pfizer from Informachine
Pfizer Announces Positive Topline Phase 3 Results for LITFULO in Patients with Nonsegmental Vitiligo
30 Jul 2026
Two pivotal studies of LITFULO™ (ritlecitinib) in nonsegmental vitiligo met their co-primary endpoints, showing significant improvement in facial and total repigmentation versus placebo at Week 52 LIT
European Commission Authorizes Pfizer and BioNTech XFG-adapted COVID-19 Vaccine in the European Union
30 Jul 2026
Data indicate that the 2026-2027 COVID-19 vaccine formula, targeting the XFG variant, induces a strong immune response against contemporary circulating and emerging lineages More than five billion dos
FDA Grants Priority Review for Pfizer’s TALZENNA Plus XTANDI for the Treatment of Metastatic Prostate Cancer
23 Jul 2026
Supplemental application aims to expand use to men with HRR gene-mutated metastatic castration-sensitive prostate cancer Filing supported by Phase 3 TALAPRO-3 data demonstrating greater than 50% impro
U.S. FDA Approves PADCEV® plus Keytruda® as Neoadjuvant and Adjuvant Treatment for Muscle-Invasive Bladder Cancer Regardless of Cisplatin Eligibility
14 Jul 2026
First and only treatment regimen for adults with MIBC, regardless of cisplatin eligibility, representing a platinum-free potential standard of care Broadened approval supported by Phase 3 EV-304 data
Pfizer Declares Third-Quarter 2026 Dividend
02 Jul 2026
Board of Directors approves quarterly cash dividend of $0.43 per share Pfizer Inc. (NYSE: PFE) today announced that its board of directors declared a $0.43 third-quarter 2026 dividend on the company’s
FDA Approves Pfizer’s IBRANCE Regimen for HR+, HER2+ Metastatic Breast Cancer Frontline Maintenance
02 Jul 2026
First and only CDK4/6 inhibitor approved for HR+ metastatic disease regardless of HER2 status Approval based on data from the collaborative Phase 3 PATINA trial, which showed a 24% risk reduction in d
Pfizer Invites Public to View and Listen to Webcast of August 4 Conference Call with Analysts
02 Jul 2026
Pfizer Inc. (NYSE: PFE) invites investors and the general public to view and listen to a webcast of a conference call with investment analysts at 10:00 a.m. EDT on Tuesday, August 4, 2026. The purpose
Pfizer Announces Chief Financial Officer Transition
19 Jun 2026
Pfizer Inc. (NYSE: PFE) today announced that Dave Denton, Chief Financial Officer, will step down from his current role and leave the company on August 15 for a professional opportunity outside of the
Robust Phase 2b Efficacy and Favorable Tolerability Support Monthly Dosing for Pfizer’s GLP-1 RA Berobenatide
06 Jun 2026
Results from multiple Phase 2b dose finding studies for berobenatide (PF’3944) highlight a potential first-in-class monthly GLP-1 receptor agonist (GLP-1 RA) peptide, and support the planned Phase 3 l
Pfizer and Innovent Biologics Enter Global Strategic Collaboration to Accelerate Development of Innovative Oncology Medicines
29 May 2026
Pfizer Inc. (NYSE: PFE) and Innovent Biologics, Inc. (01801.HK), today announced the companies have entered into a strategic global licensing and collaboration agreement for the research and developme
